IFIris Feng

Iris Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iris Feng has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Koji Takeda

    Division of Cardiothoracic and Vascular Surgery, Columbia University Medical Center, New York, USA

    5 shared publications
  • Farhana Latif

    Advanced Heart Failure and Transplant Cardiology New York Presbyterian Hospital, Columbia University Medical Center New York New York USA

    3 shared publications
  • Nir Uriel

    Advanced Heart Failure and Transplant Cardiology New York Presbyterian Hospital, Columbia University Medical Center New York New York USA

    3 shared publications
  • Yoshifumi Naka

    Cardiothoracic Surgery Weill Cornell Medical Center New York New York USA

    3 shared publications
  • Yuji Kaku

    Division of Cardiothoracic and Vascular Surgery New York Presbyterian Hospital, Columbia University Medical Center New York New York USA

    3 shared publications
  • Christine Yang

    Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA

    2 shared publications

Latest Publications

  • Operative Details and Clinical Outcomes of Chordal Preservation in Mitral Valve Replacement Surgery

    by James Lao, Iris Feng, Berk Inan, Ian Mason, Megan Chung, Darina Kirilina, Marco Tagliafierro, Kavya Rajesh, Makoto Mori, Paul Kurlansky, et al.

  • Impact of Donor and Recipient Sex‐Mismatch in Donation After Circulatory Death Heart Transplant

    by Kavya Rajesh, Iris Feng, Farhana Latif, Gabriel Sayer, Nir Uriel, Yuji Kaku, Yoshifumi Naka, Paul Kurlansky, Koji Takeda

    Background: Prior studies have demonstrated an association between donor/recipient sex mismatch and worse outcomes in donation after brain death (DBD) heart transplant. This study aims to determine the impact of donor/recipient sex mismatch on outcomes in donation after circulatory death (DCD) transplant. Methods: The study cohort consisted of 1260 patients from the United Network for Organ Sharing (UNOS) dataset who underwent DCD heart transplant between 12/2019 and 12/2023. Transplants were stratified into four groups: female donor/female recipient (FD/FR), female donor/male recipient (FD/MR), male donor/male recipient (MD/MR), and male donor/female recipient (MD/FR). The primary outcomes were acute rejection and post‐operative complications, while the secondary outcome was mortality. Multivariable logistic regression was used to analyze factors associated with rejection, while Kaplan–Meier (KM) survival analyses were compared using the log‐rank test with post‐hoc binary comparisons. Results: Female recipients who received DCD transplant had higher rates of acute rejection compared to male recipients (FD/FR: 26 (20%), MD/FR: 28 (22.2%), MD/MR 110 (11.8%), FD/MR 6 (9%), p = 0.001) while rates of stroke, dialysis, and pacemaker implantation were similar. Among male recipients, weight, height, and left ventricular assist device (LVAD) were associated with acute rejection. However, neither weight nor height was associated with acute rejection in female recipients. The KM curve showed no difference in long‐term mortality. Conclusions: Female recipients who receive DCD hearts from male and female donors have an increased risk of acute rejection compared to their male counterparts. Height and weight are associated with acute rejection in male patients. Male and female recipients have similar long‐term mortality.


  • Open Access

    Impella 5.5 use in women: A multicenter study

    by Michaela Asher, David Rekhtman, Amit Iyengar, John DePaolo, Cindy Song, Iris Feng, Emma Morganroth, Gabriel Dardik, Max Shin, Noah Weingarten, et al.


  • Outcomes of Donor‐Recipient Size Mismatch in Donation After Circulatory Death Heart Transplantation

    by Iris Feng, Kavya Rajesh, Yanling Zhao, Farhana Latif, Gabriel T. Sayer, Nir Y. Uriel, Yoshifumi Naka, Paul A. Kurlansky, Koji Takeda

    Introduction: Prior studies of donor‐recipient size mismatch only included donation after brain death heart transplants. Given higher rates of primary graft dysfunction, identifying optimal graft selection factors specific to donation after circulatory death (DCD) is crucial. We assessed outcomes of size mismatch in DCD heart transplants based on predicted heart mass (PHM), height, and weight.Methods: The study cohort consisted of 1631 adult patients from the United Network for Organ Sharing dataset who underwent DCD heart transplant between 12/1/2019 and 6/30/2024. Size mismatch was categorized based on donor/recipient ratio: >15% difference for weight and PHM, and >5% difference for height. The primary outcome was post‐transplant mortality. Median follow‐up time was 359 days with an interquartile range of 165.2–677.5 days.Results: Stratification by height mismatch resulted in 257 (15.8%) undersized, 1062 (65.1%) size‐matched, and 312 (19.1%) oversized donor‐recipient pairs. Multivariable logistic regression analysis found that oversized height was independently associated with a significantly greater risk of in‐hospital mortality (OR [95% CI]: 2.106 [1.161, 3.822], p = 0.014), while weight and PHM mismatch remained non‐significant. Multivariable Cox regression was also performed for longer term mortality by including all mortality events through time of last follow‐up, and again found that oversized height was independently associated with the outcome (HR [95% CI]: 1.737 [1.181, 2.555], p = 0.005) while weight and PHM mismatch were not.Conclusions: Donor‐recipient height oversizing by >5% was associated with a greater risk of early and mid‐term mortality after DCD heart transplantation.


  • Mid-Term Outcomes of Valve-Sparing Repair With Intraoperative Balloon Dilation in Tetralogy of Fallot

    by Morgan K. Moroi, Iris Feng, Alice V. Vinogradsky, Christine G. Yang, Stephanie N. Nguyen, David M. Kalfa, Andrew B. Goldstone, Emile A. Bacha

    Background: Late sequelae associated with chronic severe pulmonary regurgitation (PR) following transannular patch (TAP) repair of tetralogy of Fallot (TOF) have driven the use of alternative approaches. This study investigates mid-term pulmonic valve (PV) durability in TOF patients who underwent valve-sparing repair with intraoperative balloon dilation (VS-IBD). Methods: Between 2010 and 2022, 139 TOF patients underwent VS-IBD (n = 66) or TAP (n = 73) repair at a single institution. Patients who underwent VS repair without IBD were excluded. Baseline differences were balanced by inverse probability of treatment weighting (IPTW). Primary outcome was freedom from reintervention, with median follow-up of 4.6 years. Results: Valve-sparing repair with intraoperative balloon dilation patients were older (117 vs 64 days, P = .001) with higher PV annulus z-scores (−2.26 vs −2.62, P = .001) compared with TAP patients. After IPTW, VS-IBD patients had a higher reintervention rate (12.6% vs 2.2%, P = .028). At five years, 37/66 (56%) of VS-IBD patients remained free from ≥ moderate PR and 56/66 (85%) free from ≥ moderate pulmonic stenosis (PS). At the latest follow-up, VS-IBD patients demonstrated less right ventricular (RV) dilation (severe: 1.0% vs 15.5%, P = .002) and similar RV function (normal: 88.0% vs 91.8%, P = .273) as their TAP counterparts. In multivariable Cox analysis of VS-IBD patients, female sex (hazard ratio, HR [95% confidence interval, CI]: 4.4 [1.5, 13.2], P = .008) and preoperative PV z-score −2.67 to −2.18 (HR [95% CI]: 5.7 [1.6, 19.6], P = .006) were risk factors for developing ≥ moderate PR. Conclusions: Despite a higher early reintervention rate, the trade-off for VS-IBD patients appears to be better-preserved valve competency overall, as well as less adverse RV remodeling.

  • Outcomes of emergency medical service transport on venoarterial extracorporeal life support in cardiogenic shock

    by Christine Yang, Iris Feng, Paul Kurlansky, Kathryn Fidlow, Dana A Mullin, Melana Yuzefpolskaya, Paolo C. Colombo, Gabriel Sayer, Nir Uriel, Yuji Kaku, et al.

    Introduction: Veno-arterial extracorporeal life support (V-A ECLS) can be utilized to transport cardiogenic shock patients from a regional to a tertiary center. Mobile extracorporeal membrane oxygenation (ECMO) may be life-saving for critically ill patients to bridge to transplant or a higher level of care. Methods: This study is a retrospective review of adult patients placed on V-A ECMO for cardiogenic shock between 2018 and 2022. Indications and outcomes were compared between patients who were cannulated at referring hospitals and transported via ambulance and those who were placed on VA-ECLS at our institution. Results: 547 patients with V-A ECMO placed due to cardiogenic shock were included. 94 patients were transported from referring hospitals, while 453 were placed on V-A ECMO at our institution. All were safely transported. In-hospital mortality was significantly higher in transport patients (49.1% vs 59.5%, p = .042). Transport patients had significantly higher rates of acute kidney injury requiring dialysis (27.8% vs 39.4%, p -value = .035) and cerebrovascular accident (6.2% vs 12.8%, p -value = .026). Kaplan-Meier curves showed 6-month survival was significantly lower in transport group (48.5% vs 37.3%, p = .021). Multivariate analysis demonstrated ECMO indication of AMI (OR 1.43, p -value = .037), ECPR (OR 2.45, p -value <.001), and history of COPD (OR 1.55, p -value = .014) were predictors of mortality within 12 months. Notably ECMO transport was not a significant risk factor. Conclusions: Patients transported on V-A ECMO had higher in-hospital mortality, as well as lower 1-year survival. Careful patient selection is required.


  • Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support

    by Iris Feng, Tanner R. Powley, Christine G. Yang, Paul A. Kurlansky, Lauren D. Sutherland, Jonathan M. Hastie, Yuji Kaku, Justin A. Fried, Koji Takeda

    Introduction: No clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated partial thromboplastin time (aPTT) strategies for UFH monitoring during VA-ECLS. Methods: This is a single-center, retrospective review of VA-ECLS patients who received UFH in the cardiothoracic intensive care unit between July 2019 and November 2023. Standard protocol for UFH titration was aPTT goal of 45-60 sec ( n = 52) before September 2021, then transitioned to FXa goal of 0.1-0.2 U/mL ( n = 50) thereafter. Inverse probability of treatment weighting was used to balance baseline differences between cohorts. Results: In adjusted analyses, 89.3% of FXa patients and 76.0% of aPTT patients achieved goal range for their respective assay. Total UFH duration (4.0 vs 4.0 days, p = .239) and maximum weight-adjusted UFH dose (9.3 vs 9.4 U/hr/kg, p = .823) remained comparable between adjusted FXa and aPTT cohorts. Moreover, in-hospital mortality (50.3% vs 33.9%, p = .133), major bleeding events (20.6% vs 11.2%, p = .292), and thromboembolic events (30.1% vs 30.1%, p = .998) were not significantly different. Extracorporeal circuit thrombosis and cannula site bleeding were the most frequent events in both groups. Multivariate logistic regression found the FXa strategy was not a significant risk factor for the composite outcome of major bleeding or thromboembolism (OR [95% CI]: 1.539 [0.575, 4.116], p = .393). Conclusions: In adult VA-ECLS patients at our institution, bleeding and thromboembolic complications occurred at a similar rate regardless of which UFH monitoring strategy was utilized. Further studies in larger and more institutionally diverse cohorts are warranted.


  • Bridge to simultaneous heart-kidney transplantation via extracorporeal life support: National outcomes in the new heart allocation policy era

    by Iris Feng, Paul A. Kurlansky, Yanling Zhao, Krushang Patel, Morgan K. Moroi, Alice V. Vinogradsky, Farhana Latif, Gabriel Sayer, Nir Uriel, Yoshifumi Naka, et al.


  • Open Access

    Stromal Pbrm1 mediates chromatin remodeling necessary for embryo implantation in the mouse uterus

    by Qiliang Xin, Iris Feng, Guoyun Yu, Jurrien Dean

    Early gestational loss occurs in approximately 20% of all clinically recognized human pregnancies and is an important cause of morbidity. Either embryonic or maternal defects can cause loss, but a functioning and receptive uterine endometrium is crucial for embryo implantation. We report that the switch/sucrose nonfermentable (SWI/SNF) remodeling complex containing polybromo-1 (PBRM1) and Brahma-related gene 1 (BRG1) is essential for implantation of the embryonic blastocyst on the wall of the uterus in mice. Although preimplantation development is unaffected, conditional ablation of Pbrm1 in uterine stromal cells disrupts progesterone pathways and uterine receptivity. Heart and neural crest derivatives expressed 2 (Hand2) encodes a basic helix-loop-helix (bHLH) transcription factor required for embryo implantation. We identify an enhancer of the Hand2 gene in stromal cells that requires PBRM1 for epigenetic histone modifications/coactivator recruitment and looping with the promoter. In Pbrm1cKO mice, perturbation of chromatin assembly at the promoter and enhancer sites compromises Hand2 transcription, adversely affects fibroblast growth factor signaling pathways, prevents normal stromal-epithelial crosstalk, and disrupts embryo implantation. The mutant female mice are infertile and provide insight into potential causes of early pregnancy loss in humans.